Tilray Acquires HelloMD to Build Out Canadian Medical Cannabis Network

NEW YORK – Tilray Brands Inc. has agreed to acquire HelloMD Corporation’s Canadian medical Cannabis assets, in a deal the companies say will build a fully vertically integrated medical Cannabis structure in Canada and add a digital healthcare platform to Tilray’s broader operations.

Tilray was named the winning bidder in HelloMD’s formal sale process, and closing remains contingent on court approval, which the companies expected to receive on June 29, 2026.
Financial terms of the transaction were not disclosed.

HelloMD operates a telehealth platform that connects patients with physicians for medical Cannabis consultations, alongside education resources and ongoing patient support. The company said its platform has served hundreds of thousands of patients since its founding through telehealth visits, educational content and personalized guidance.

Blair MacNeil, president of Tilray Canada, said the deal builds out the company’s footprint by “expanding patient engagement, practitioner support, and access” in regulated medical markets. Larry Lisser, HelloMD’s CEO, framed the sale around the company’s long-standing focus on widening access to medical Cannabis through technology, education and trusted healthcare relationships.

For Tilray, the purchase extends a structure already in place across cultivation, clinical support and product distribution in Canada. Company executives said the addition gives Tilray a way to reach eligible patients earlier in their treatment decisions, rather than only after other options have been exhausted, and to position regulated cannabis products within a broader category of natural health options.

Tilray supplies medical Cannabis to patients, physicians, hospitals, pharmacies, researchers and governments across twenty countries on five continents, distributing under brands including Tilray Medical, Good Supply, Redecan, ARX and Broken Coast. Its medical infrastructure already includes EU-GMP certified cultivation and manufacturing, pharmaceutical distribution through CC Pharma, and clinics across North America, Europe and Australia.

The acquisition follows a stretch in which Tilray shares have traded near multi-year lows, having declined sharply over the past six months even after Cannabis stocks broadly rallied following the U.S. Department of Justice’s reclassification of state-licensed medical Cannabis under Schedule III.

Wrapping up, the HelloMD acquisition reads as another example of multinational Cannabis operators absorbing healthcare-adjacent technology to reach patients earlier in their treatment decisions, rather than competing on shelf price alone. Tilray’s wager is that a platform built around physician access, education and patient trust can do more for long-term retention than product variety alone.